Industry panellists at the LSX Investival Showcase Europe outlined practical strategies for biotechs to navigate the funding ‘‘valley of death’’ between seed rounds and commercialization. Speakers from Blackstone, Limerston Capital and Apposite Capital emphasized investors now demand differentiated, matured platforms and clinical validation prior to large commitments. Panelists recommended alternative financing such as royalty and revenue‑based structures, and urged founders to prioritize translational readiness and clear commercialization pathways. The discussion underscores a tightening financing environment where capital remains available but conditional on de‑risked science and near‑term paths to revenue.